Company

Location:Home > Company > Press Release > 2013

CapitalBio Launches Molecular Diagnostic Assay Service in Beijing

Time:2013-01-23

 

(Jan 21st 2013, Beijing) CapitalBio has commenced offering molecular diagnostic assay services at their new standalone facility, about 60 kilometers to the south east of their Beijing headquarters. The current services include a range of molecular diagnostic tests, both microarray-based assays and PCR assays, and will soon extend to mass spectrometry and sequencing later in 2013. The facility, named the CapitalBio Independent Clinical Laboratory, is supervised by Chinese Ministry of Health, and is licensed to offer Chinese SFDA approved IVD assays. In the long run, it is expected to also offer a wide range of laboratory developed tests.

 

新聞

CapitalBio Medical Affairs VP, Chuan ZHANG, and International Business VP, Keith Mitchelson catch the first ray of winter sun beaming into the CapitalBio Independent Clinical Laboratory. 

The new CapitalBio laboratory facility is engaged in the provision of a free neonatal deafness gene mutation screening, a project supported by the Beijing municipal government in 2012, with a total of about 200,000 microarray tests to be completed by the end of March 2013. The laboratory which currently has a peak volume of 1,800 tests per day, and plans to scale up the capacity by four times with the introduction of LabKeeper 8, a new integrated, automatic liquid handling and sample preparation system developed by CapitalBio.

 

 

新聞1

The sample preparation and analysis capacity of the current workflow is 1800 tests per day.  

The Laboratory focuses on the personal diagnostics and molecular genetic assays for inherited diseases, carcinomas, cardiovascular diseases, metabolic diseases, and high-end health management services. The mission of the facility is to become a center of excellence to develop and promote LDTs for clinical settings, and for CapitalBio innovation and other cutting edge technologies for use in translational medicine, and thus rationalize and optimize the processing of medical interventions.

 

新聞2

The CapitalBio Independent Clinical Laboratory facility.

 

 

 

四川血战麻将大胡有哪些 四川熊猫麻将手机版 舟山飞鱼彩票走势分析 快乐双彩基本分布走势图 捕鱼大师稳赢版现金版 下载广东闲来麻将 天天乐湖北棋牌作弊器 体育彩票玩法介绍大全 加拿大快乐8开奖官方网站 浙江体彩十一选五一定牛 陕西省快乐十分开奖结果今天 大圣闹海捕鱼平台 河南紫幻麻将2019最新安卓版 欢聚棋牌代理微信 kk棋牌游戏客服电话 黑龙江22选五开奖号 体彩安徽十一选五走势图